enow.com Web Search

  1. Ads

    related to: secondary progressive ms treatment 2023 calendar

Search results

  1. Results from the WOW.Com Content Network
  2. Multiple sclerosis drug pipeline - Wikipedia

    en.wikipedia.org/wiki/Multiple_sclerosis_drug...

    The appropriate pathway to put forward masitinib through the regulatory agencies, for the treatment of progressive forms of multiple sclerosis, is under study [34] evobrutinib is a selective oral Bruton's tyrosine kinase (BTK) inhibitor that has been shown to inhibit B-cell activation both in vitro and in vivo.

  3. Siponimod - Wikipedia

    en.wikipedia.org/wiki/Siponimod

    Siponimod is indicated for the treatment of secondary progressive multiple sclerosis, which is the progressive neurological decline of multiple sclerosis that happens independent of acute relapses. [1] In active secondary progressive multiple sclerosis, siponimod decreases the risk of disability and multiple sclerosis relapses. [1]

  4. Management of multiple sclerosis - Wikipedia

    en.wikipedia.org/wiki/Management_of_multiple...

    In March 2017, ocrelizumab was approved in the United States for the treatment of primary progressive multiple sclerosis in adults. [22] [42] It is also used for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. [42]

  5. Press Release: Tolebrutinib demonstrated a 31% delay in time ...

    lite.aol.com/tech/story/0022/20240920/1000992889.htm

    Positive results from the HERCULES phase 3 study in people with non-relapsing secondary progressive multiple sclerosis (nrSPMS) demonstrated that tolebrutinib delayed the time to onset of 6-month confirmed disability progression (CDP) by 31% compared to placebo (HR 0.69; 95% CI 0.55-0.88; p=0.0026).

  6. Glatiramer acetate - Wikipedia

    en.wikipedia.org/wiki/Glatiramer_acetate

    Glatiramer acetate (also known as Copolymer 1, Cop-1), sold under the brand name Copaxone among others, is an immunomodulator medication used to treat multiple sclerosis. [1] [2] Glatiramer acetate is approved in the United States to reduce the frequency of relapses, but not for reducing the progression of disability.

  7. Sanofi's tolebrutinib drug delays progressive MS by 31% in trial

    www.aol.com/news/sanofis-tolebrutinib-drug...

    FRANKFURT (Reuters) -Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the French drugmaker eyes a ...

  1. Ads

    related to: secondary progressive ms treatment 2023 calendar